All About Multiple Sclerosis

More MS news articles for November 2002

Vaccine for autoimmune diseases may soon be a reality

http://www.navakal.com/news/health/200210293007.asp

Oct 29, 2002
Nicosia,  (ANI):

Vaccine for autoimmune diseases, like rheumatoid arthritis and multiple sclerosis, may very well be on the horizon, thanks to promising animal test results.

In two related papers published in the September issue of Journal of Immunology, researchers from the Technion-Israel Institute of Technology said that the vaccine reversed an arthritic-like disease in rats by mobilizing part of the immune system to protect joints under attack by other immune cells.

Current treatments for autoimmune diseases involve either steroids, which fight inflammation caused by the immune system attacks, or immuno-suppressant drugs, which depress immune system function generally. Both these approaches tend to lead to serious side-effects and can only slow, but not stop, the progress of the diseases. They are also effective mostly at very early stages of each disease.

In contrast, the new approach tries to rally one part of the immune system - the so-called "good" part - to fight the part that is attacking the bodys tissues - the "bad" or autoimmune part.

"We know that, in autoimmune diseases, immune cells use chemical markers, called cytokines and chemokines, to induce inflammation that destroys organs. These proteins also attract white blood cells that, in the case of arthritis, attack joint tissues, and in the case of MS, attack brain components. Our method helps the immune system itself interfere with this process," said Dr Nathan Karin of the Technions Department of Immunology and the research team leader.

The researchers first identified that IP-10 is one of the specific proteins responsible for the progression of these diseases, and more importantly that the immune system tries to restrain the harmful activity of IP-10 by producing auto- antibodies against it. They then generated a special vaccine that amplifies the production of these beneficial antibodies. This vaccine rapidly suppressed experimentally induced rheumatoid arthritis and MS.

Dr Karin hopes that for rheumatoid arthritis this approach will replace older treatments, which are extremely expensive and require many repeated immunizations, and that it will also open new horizons for the therapy of MS.

"We are hopeful that the gene-based vaccine will be much better, since only a few vaccinations are needed to train the immune system to destroy IP-10, and the rat results indicate that chronic relief may be possible," he added.

While the vaccine will interfere with IP-10 when the immune system uses it to label actual invaders such as bacteria, Dr Karin does not expect this will cause serious side-effects.

"There are some 50 chemicals that the immune system uses to label cells to be attacked. Knocking out one will not seriously weaken the immune systems response to infection or cancer. But in autoimmune diseases, where one part of the immune system is fighting another, eliminating IP-10 will shift the balance, giving the edge to the part that is protecting the body," he added.

The next step is to move towards clinical tests of the vaccine in humans.
 

© Copyright  Navakal,Inc